UK - Quester exits Oxxon Therapeutics

Quester-backed biopharmaceutical company Oxxon Therapeutics has been acquired by London Stock Exchange-listed Oxford BioMedica Plc for £16m. The sale to Oxford BioMedica, a company previously backed by Prelude Trust before being floated, represents a partial exit for Quester and co-investors Isis College Fund, NIF Ventures, Gray Ghost, NVM and Neomed Innovation ASA. The acquisition of Oxxon provides Oxford BioMedica with a cancer immunotherapy product candidatre to complement its own such candidate and adds to its gene-based medicine portfolio.